At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
eltrombopagdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Repeat Dosing Study of Eltrombopag Olamine (SB-497115-GR) in Adult Subjects, With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
In Brief
A Phase 2 clinical trial evaluating eltrombopag for Purpura, Thrombocytopaenic, Idiopathic. Completed, enrolled 66 participants across 3 sites in 2 countries.
Detailed Summary
This open-label, repeat dosing study, TRA108057, will evaluate the efficacy, safety and tolerability of eltrombopag, when administered in a repeat, cyclic dosing schedule. The study will describe the effect of repeated (3 cycles), intermittent dosing of eltrombopag on the pharmacodynamics and durability of eltrombopag response as measured by the peripheral platelet counts. For more information or to see if you qualify, please visit: http://www.itpstudy.com/gov
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPurpura, Thrombocytopaenic, Idiopathic
CountriesGermany, Russia
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2007
Enrollment StartMar 2007
Primary CompletionAug 2008
Study CompletionNov 2008
TodayJul 2026
First PostedJan 18, 2007
Enrollment StartMar 1, 2007
Primary CompletionAug 1, 2008
Study CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.5 years ago
Interventions
eltrombopagdrug
experimental